The notices it replaced
- Reissues: RFA-OD-20-003 Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)
Replaced by RFA-OD-27-005.
Who won it before
8 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,370,928 in first-year total cost, median $622,375.
Most frequent study sections
- Special Emphasis Panel[ZRG1 VH-N (90)]4
- Special Emphasis Panel[ZRG1 IVBH-B (56)]2
- Special Emphasis Panel[ZRG1 BBBP-J (55)]1
- Special Emphasis Panel[ZRG1 IVBH-A (56)]1
Most frequent institutions
- UNIVERSITY OF COLORADO DENVER2
- CINCINNATI CHILDRENS HOSP MED CTR1
- COLORADO STATE UNIVERSITY1
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
- OREGON HEALTH & SCIENCE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Home Grown: A family-based lifestyle intervention to support healthy development of young children with Down syndrome1R61HD118439-01 | WILLIS, ERIK A | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $1,017,548 | ZRG1 |
| 2024 | Executive Function Intervention for Young Children with Down Syndrome1R61HD115161-01 | FIDLER, DEBORAH J | COLORADO STATE UNIVERSITY, CO | $694,434 | ZRG1 |
| 2024 | Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome1R61AR084210-01 | BOGUNOVIC, DUSANGUTTMAN, EMMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $299,120 | ZRG1 |
| 2022 | Randomized Control Trial of oxygen therapy in Children and Adolescents with Down Syndrome and Obstructive Sleep Apnea1R61HL165366-01 · under RFA-OD-20-003 | AMIN, RAOUF S.REDLINE, SUSAN S. | CINCINNATI CHILDRENS HOSP MED CTR, OH | $2,841,336 | ZRG1 |
| 2022 | Treatment of Obstructive Sleep Apnea with Personalized Surgery in Children with Down Syndrome (TOPS-DS)1R61HL165345-01 · under RFA-OD-20-003 | LAM, DEREK J | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $1,253,610 | ZRG1 |
| 2022 | The Impact of Weight Loss on Alzheimer's Disease Risk in Adults with Down Syndrome1R61AG078967-01 · under RFA-OD-20-003 | PTOMEY, LAUREN TAYLORSULLIVAN, DEBRA K | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $550,315 | ZRG1 |
| 2022 | Mechanistic investigation of therapies for Down Syndrome Regression Disorder1R61HD109748-01 · under RFA-OD-20-003 | ESPINOSA, JOAQUIN M.SANNAR, ELISE MSANTORO, JONATHAN DOUGLAS | UNIVERSITY OF COLORADO DENVER, CO | $369,021 | ZRG1 |
| 2021 | GM-CSF/sargramostim treatment to improve cognition in Down syndrome1R61AG074859-01 · under RFA-OD-20-003 | POTTER, HUNTINGTONPRESSMAN, PETER SCOTT | UNIVERSITY OF COLORADO DENVER, CO | $345,544 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.